Trade Nektar Therapeutics

We Choose Therapeutics (Nektar) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying proprietary PEGylation and advanced polymer pairing technologies to modify the chemical composition of the substances. It is a technology supplier for a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first non-injectable insulin, Exubera, which was awarded a bronze award by the Wall Street Journal for its technological breakthrough. the company is involved in the development of a proprietary pipeline of candidates for drugs for several areas of treatment including oncology, pain, infection control, antivirus and immunology. The company's research and development involves a small molecule and biologic drug candidates. The drug filter base consists of naloxegol (Movantik), an oral opioid antagonist in phase III, and pegol etirinotecan, a topoisomerase inhibitor under the third stage of clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc. In 2013, a patent was allocated to the company developed by the company and four other co-inventors. The company's products are offered as a supplement to improve pharmaceuticals, pharmaceutical cosmetics, half-life, bioavailability and other pharmaceutical areas for patients worldwide. As of March 2014, the company had a market value of $1.7 billion at $1.67 billion. As of July 15, 2019, the company's market cap was $5.88 billion.